Please assess the completion status of the following clinical trial:

Trial Title: Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 9 to 16 years on the day of inclusion and resident of the site zone~* Participant in good health, based on medical history and physical examination~* Assent form or informed consent form has been signed and dated by the participant (based on local regulations), and informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (and by an independent witness if required by local regulations)~* Participant was able to attend all scheduled visits and comply with all trial procedures.~Exclusion Criteria:~* Participant was pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination).~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Self-reported or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)~* Self-reported seropositivity for Human Immunodeficiency Virus (HIV) infection~* Self-reported systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances~* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion~* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response~* Planned receipt of any vaccine in the 4 weeks following any trial vaccination~* Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily~* Current alcohol abuse or drug addiction that may interfere with the participant's ability to comply with trial procedures~* Identified as a site employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as a family member (i.e., immediate, husband, wife and their children, adopted or natural) of the site employees or the Investigator.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- CYD Dengue Vaccine Group (Type: EXPERIMENTAL): Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.
- Placebo Group (Type: PLACEBO_COMPARATOR): Participants were to receive a placebo vaccine at 0, 6, and 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete